|Articles|June 23, 2017

Understanding the role of inflammation in dry eye

Optometry Times Editorial Advisory Board members Leslie E. O’Dell. OD, FAAO, and Scott Hauswirth, OD, FAAO, discuss their recent lecture on inflammation and the role it plays in ocular surface diseases at the American Optometric Association’s Optometry’s Meeting in Washington, DC.

Optometry Times Editorial Advisory Board members Leslie E. O’Dell. OD, FAAO, and Scott Hauswirth, OD, FAAO, discuss their recent lecture on inflammation and the role it plays in ocular surface diseases at the American Optometric Association’s Optometry’s Meeting in Washington, DC.

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Understanding the role of inflammation in dry eye

Related Content

Orasis Pharmaceuticals, BlinkRx partnership offers new dispensing options for Qlosi

Detoxifying for visual longevity

FDA approves Outlook Therapeutics' Lytenava for wet AMD

Rethinking OCT biomarkers in DME: Baseline acuity and thickness outperform the rest

iVeena completes end-of-phase 1 FDA meeting for IVMED-85 in myopia

Latest CME

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

PER Global Perspectives: Differentiating and Managing Toxicities with TROP2-Targeted ADCs in NSCLC Through Multidisciplinary Pathways

Une Vision d’Espoir: Lighting the Way in GA Management & Treatment

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

Medical Crossfire®: Maximizing Durability Across Retinal Disease — What 3 Years of Evidence Means for Your Practice

AREDS3 and Beyond: The Scientific Basis for B Vitamin Nutritional Supplementation in AMD

EyeCon 2026

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Trending on Optometry Times - Clinical News & Expert Optometrist Insights

FDA approves Outlook Therapeutics' Lytenava for wet AMD

Detoxifying for visual longevity

Orasis Pharmaceuticals, BlinkRx partnership offers new dispensing options for Qlosi

iVeena completes end-of-phase 1 FDA meeting for IVMED-85 in myopia

Rethinking OCT biomarkers in DME: Baseline acuity and thickness outperform the rest